Press Releases
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit
Dr. Martin Tolar to Provide an Update on Alzheon’s ALZ-801 Phase 3 Program and Join Panel Discussion on Current Research in Alzheimer’s Disease.
Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease
Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials.
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
Study to Evaluate ALZ-801 Effects on Alzheimer’s Biomarkers Associated with Clinical BenefitIncludes Comprehensive Biomarker Assessment to Accelerate Development of ALZ-801 for Alzheimer’s Disease PreventionFacilitates Biomarker-Enabled Indication Expansion [...]
Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease
Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer’s Disease in Patients with APOE4/4 Genetic ProfileGrant Supports Advancement of the First Oral Agent with [...]
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker ResultsSelectivity for Amyloid [...]
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
FRAMINGHAM, Mass., January 7, 2020 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative [...]